Benefits Redefined Episodes

Richard Silberstein

Full episodes of the podcast

Episodes

  1. Jun 3

    Ep 9: Captives, Reserves, and How CFOs Are Rethinking Health Plan Risk

    "Are we reserving appropriately? If we have a bad year next year, what's it going to cost the partners?" It's the question Richard Silberstein heard from a CEO at a coffee shop, and it's the same question CFOs of self-insured employers are asking across the country right now. In this episode of Benefits Redefined, Richard is joined again by Prabal Lakhanpal, National Practice Leader for Alternate Risk and Captives at Alera Group, to unpack how to actually answer it. They cover: →  How to evaluate whether your medical claims reserves are appropriate, using Monte Carlo simulation and confidence level analysis →  Why most auditors will not accept reserves above the 70-80% confidence threshold, and what that means for partnership tax planning →  The difference between being a buyer of insurance and a trader of insurance, and why captives change the math →  Why medical stop loss is priced like a 1-in-1 year event when the coverage is built for 1 in 5 →  How combining short tail risks like stop loss with long tail risks like workers comp creates a diversified, more stable portfolio →  The 500 employee, $2 million premium threshold where alternate risk strategies start to make sense →  How adding employee benefits to an existing property and casualty captive can drive admin cost efficiency straight to the bottom line →  Group captives as the solution for smaller employers who want access without the infrastructure build →  Where fiduciary duty intersects with captive strategy, and why CFOs and HR leaders should be in the same conversation Whether you're a CFO weighing alternate risk, an HR leader trying to bring enterprise thinking to your benefits strategy, or a benefits committee member wrestling with reserve adequacy, this conversation gives you a working framework. GUEST Prabal Lakhanpal, National Practice Leader, Alternate Risk and Captives, Alera Group | https://www.linkedin.com/in/praballakhanpal/ Want to learn more? Connect with Richard via our website: www.benefitsredefined.com  Subscribe to stay up to date with the latest episodes.

    30 min
  2. Apr 23

    Ep 2: Most Employers Are Overpaying for Pharmacy Benefits (Here’s Why)

    Want to learn more? Visit our website: https://www.benefitsredefined.com   Pharmacy spend is quickly becoming one of the largest and least understood drivers of employer healthcare costs. Many employers assume these costs are unavoidable—but that’s often not the case.   In this episode of Benefits Redefined, Richard speaks with Jennifer Perlitch, Clinical Pharmacist, about what employers are missing when it comes to pharmacy benefits and why looking “under the hood” of your PBM and drug data can reveal significant savings opportunities.   Jennifer works directly with employers reviewing pharmacy claims, contracts, and utilization patterns to uncover hidden costs, missed rebates, and opportunities to improve both outcomes and spending.   If you’re responsible for benefits strategy, healthcare budgets, or financial planning, this conversation will help you understand where pharmacy costs are really coming from—and what smart employers are doing differently.   In this episode, you’ll learn:   - Why many employers are unknowingly overpaying for GLP-1 medications and what alternatives may dramatically reduce costs.   - How PBM rebate structures actually work—and why shrinking rebates and “rebate credits” could significantly impact employer budgets in 2026 and beyond.   - What specialty drugs and biosimilars mean for your plan’s future costs, and how the right strategy can prevent unexpected spikes in spend.   - The single biggest mistake employers make during PBM reviews—and the critical questions CFOs and HR leaders should be asking instead.   For many organizations, pharmacy spend is increasing faster than any other part of their health plan. The employers who manage it well are the ones who actively analyze their data, challenge their PBM contracts, and bring clinical expertise into the decision process.   If you're a CFO, CHRO, or HR executive responsible for healthcare costs, this episode will give you a clearer picture of where risks—and opportunities—may exist in your current pharmacy strategy.   If you'd like to explore whether similar opportunities exist in your plan, you can connect with Richard through the Benefits Redefined website above.   Subscribe to stay up to date with our latest episodes. Connect with Jennifer: https://www.linkedin.com/in/jennifer-perlitch-0357923/ Comment below: What has been the biggest challenge managing pharmacy costs in your organization?

    26 min

About

Full episodes of the podcast